Article
Oncology
Verena Wieser, Irina Tsibulak, Daniel Uwe Reimer, Alain Gustave Zeimet, Heidelinde Fiegl, Hubert Hackl, Christian Marth
Summary: This study investigated the expression of angiogenesis-related genes in ovarian cancer and their association with the response to bevacizumab therapy. The findings suggest that tumoral expression of PDGFA and a high transcriptional angiogenesis score are independent predictors of clinical outcome in ovarian cancer patients.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Nutrition & Dietetics
Naoko Nomoto, Shinichi Tate, Makoto Arai, Shinji Iizaka, Chisato Mori, Kenichi Sakurai
Summary: This study investigates the relationship between nutritional status before chemotherapy and chemotherapy discontinuation. The study finds that C-reactive protein-to-albumin ratio (CAR) can effectively predict the risk of chemotherapy interruption.
Article
Oncology
Hyeong In Ha, Eun Young Park, Kyung Jin Eoh, Yeon Jee Lee, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim
Summary: This study investigated the clinical significance of the ovarian cancer cluster region (OCCR) in BRCA1 and BRCA2 genes. The results showed that patients with BRCA1 pathogenic variants (PVs) in the OCCR region had shorter progression-free survival (PFS) compared to those outside the OCCR. This trend was more pronounced in the platinum-sensitive subgroup. However, no significant differences were found in overall survival (OS) between patients with BRCA1/2 PVs, regardless of the variant location.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Oncology
Domenico Ribatti, Antonio Giovanni Solimando, Francesco Pezzella
Summary: Several anti-angiogenic drugs are approved for cancer treatment, but resistance and adverse effects may occur. Combining multiple anti-angiogenic molecules or using them in combination with other treatment regimens is indicated as alternative therapeutic strategies to overcome resistance. Comprehensive omics profiling is crucial for increasing clinical benefits and overcoming resistance to anti-angiogenic therapies.
Article
Oncology
John B. Liao, William R. Gwin, Renata R. Urban, Katie M. Hitchcock-Bernhardt, Andrew L. Coveler, Doreen M. Higgins, Jennifer S. Childs, Hania N. Shakalia, Ron E. Swensen, Sasha E. Stanton, Anna Tinker, Tanya A. Wahl, Richard G. Ancheta, Kathryn F. McGonigle, James Y. Dai, Mary L. Disis, Barbara A. Goff
Summary: The study evaluated the activity and safety of pembrolizumab with carboplatin in recurrent platinum-resistant ovarian cancer, showing that this treatment approach had modest activity and good tolerability. A ratio of peripheral T-cell exhaustion to radiographic tumor burden may help identify patients who are more likely to benefit from this chemoimmunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cell Biology
Tova M. Bergsten, Sarah E. Levy, Katherine E. Zink, Hannah J. Lusk, Melissa R. Pergande, Stephanie M. Cologna, Joanna E. Burdette, Laura M. Sanchez
Summary: This study discovered that a secreted protein called SPARC, produced by tumorigenic fallopian tube epithelial cells, enhances the release of norepinephrine (NE) from the ovary, influencing the primary metastasis of high grade serous ovarian cancer (HGSOC).
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Kathleen N. Moore, Setsuko K. Chambers, Erika P. Hamilton, Lee-May Chen, Amit M. Oza, Sharad A. Ghamande, Gottfried E. Konecny, Steven C. Plaxe, Daniel L. Spitz, Jill J. J. Geenen, Tiffany A. Troso-Sandoval, Janiel M. Cragun, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M. Mugundu, Zhongwu Lai, Juliann Chmielecki, Suzanne F. Jones, David R. Spigel, Karen A. Cadoo
Summary: This study evaluated the efficacy and safety of adavosertib in combination with four chemotherapy agents for primary platinum-resistant ovarian cancer. The results showed that the combination of adavosertib and carboplatin had the most promising treatment response, but hematologic toxicity was higher than expected and further study is needed to optimize the dose and schedule.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Hyeong In Ha, Eun-Gyeong Lee, Jiwon Lim, So-Youn Jung, Yoon Jung Chang, Young-Joo Won, Myong Cheol Lim
Summary: The incidence of secondary primary POFT cancer after breast cancer increased in Korea between 1999 and 2017. Second primary POFT cancer patients were diagnosed at older ages and had more serous histology.
CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Dana M. Roque, Eric R. Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Gautam G. Rao, Jocelyn C. Reader, Pei Hui, Joan R. Tymon-Rosario, Justin Harold, Dennis Mauricio, Burak Zeybek, Gulden Menderes, Gary Altwerger, Elena Ratner, Alessandro D. Santin
Summary: This multi-center study evaluated the activity and safety of ixabepilone plus bevacizumab compared to ixabepilone alone in platinum-resistant/refractory ovarian cancer. The results showed that the combination of ixabepilone and bevacizumab had a higher overall response rate and longer progression-free survival, with good tolerability. Prior receipt of bevacizumab should not limit the use of ixabepilone plus bevacizumab in treatment.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Hideki Tokunaga, Mikio Mikami, Satoru Nagase, Yoichi Kobayashi, Tsutomu Tabata, Masanori Kaneuchi, Toyomi Satoh, Yasuyuki Hirashima, Noriomi Matsumura, Yoshihito Yokoyama, Kei Kawana, Satoru Kyo, Daisuke Aoki, Hidetaka Katabuchi
Summary: The Japan Society of Gynecologic Oncology published the fifth edition of guidelines for ovarian cancer, fallopian tube cancer, and primary peritoneal cancer treatment in 2020. The guidelines include 6 chapters and 5 algorithms, with major changes such as revised title, broader involvement, new clinical question format, and modified recommendations based on the GRADE system.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Floor J. Backes, Lai Wei, Min Chen, Kasey Hill, Kyle Dzwigalski, Ming Poi, Mitch Phelps, Ritu Salani, Larry J. Copeland, Jeffrey M. Fowler, David E. Cohn, Kristin Bixel, Casey Cosgrove, John Hays, David O'Malley
Summary: This study aimed to estimate the maximally tolerated dose and toxicities of lenvatinib and paclitaxel in patients with recurrent endometrial and platinum resistant epithelial ovarian cancer, and observed encouraging activity in both types of cancer, indicating the need for further development.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Sweta Dash, Sean Yoder, Tania Mesa, Andrew Smith, Ling Cen, Steven Eschrich, Guillermo N. Armaiz-Pena, Alvaro N. A. Monteiro
Summary: The study found that sustained adrenergic stimulation by norepinephrine has significant effects on ovarian cancer initiation and progression, particularly affecting ovarian surface epithelial cells and fallopian tube cells differently. Mutations in the p53 gene also influence the cellular response to NE stimulation.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Tadahiro Shoji, Takayuki Enomoto, Masakazu Abe, Aikou Okamoto, Takayuki Nagasawa, Tetsuro Oishi, Satoru Nagase, Masahiko Mori, Yuki Inokuchi, Shoji Kamiura, Shinichi Komiyama, Nobuhiro Takeshima, Toru Sugiyama
Summary: The study confirmed the efficacy and safety of further bevacizumab therapy in patients with platinum-resistant ovarian cancer whose disease had progressed after bevacizumab monotherapy, particularly in extending progression-free survival.
Article
Oncology
Katrin M. Sjoquist, David Espinoza, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Sonia Yip, Jeffrey Goh, David Bowtell, Michelle Harrison, Michael L. Friedlander
Summary: The study aimed to evaluate the effectiveness of intraperitoneal bevacizumab in delaying re-accumulation of malignant ascites in chemotherapy-resistant epithelial ovarian cancer patients. The results showed that IP-bev was safe, active, and could be considered as a palliative intervention for recurrent ascites.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Cell Biology
Maxence Wisztorski, Soulaimane Aboulouard, Lucas Roussel, Marie Duhamel, Philippe Saudemont, Tristan Cardon, Fabrice Narducci, Yves-Marie Robin, Anne-Sophie Lemaire, Delphine Bertin, Nawale Hajjaji, Firas Kobeissy, Eric Leblanc, Isabelle Fournier, Michel Salzet
Summary: This study conducted an in-depth proteomic analysis of pre-neoplastic epithelial lesions in ovarian cancer using mass spectrometry imaging and immunohistochemistry techniques. Specific lesion markers were identified, and a lipidomic analysis confirmed the presence of specific lipid signatures in these lesions. The study provides new insights into the molecular mechanisms underlying the progression of ovarian cancer and confirms the fimbria origin of high-grade serous carcinoma.
CELL DEATH & DISEASE
(2023)